Yoshikane Nonagase

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Koji Haratani, Hidetoshi Hayashi, Taro Tanaka et al. · Annals of Oncology · 2017 · 291 citations · Full text

Tumor Immune Microenvironment, Cancer Immunosurveillance, Medicine +11

DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance

Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka et al. · International Journal of Cancer · 2017 · 186 citations · Full text

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors

Masayuki Takeda, Takayuki Takahama, Kazuko Sakai et al. · The Oncologist · 2020 · 93 citations · Full text

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification

Naoki Takegawa, Junji Tsurutani, Hisato Kawakami et al. · International Journal of Cancer · 2019 · 89 citations · Full text

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer

Masayuki Takeda, Kazuko Sakai, Masato Terashima et al. · Annals of Oncology · 2015 · 81 citations · Full text

Oncology, Engineering, Medicine +10